Carboxylesterases in Drug Metabolism: Recording and Slides

Carboxylesterases (CES) represent an important pathway of drug metabolism. Humans, monkeys, and dogs express two, while rats and mice express up to 16 carboxylesterases. In humans, CES1 is predominately expressed in the liver and CES2 is expressed in the small intestine. The hepatic expression profile in dogs and monkeys is similar to humans. Dogs lack Ces activity in the small intestine. Monkeys, but not humans, express Ces1 in the intestine. Rodents are the only species with plasma carboxylesterase (Ces1c).

This variation in the number and tissue specificity makes interspecies extrapolation a challenge. Several factors including age, genetic polymorphism, and disease state can also affect biotransformation and efficacy of drugs that are metabolized by CES.

Although, there is a low risk of CES-mediated clinical drug-drug interactions (DDI), the potential for such DDI should not be overlooked and should be evaluated. The regulatory guidance documents including the new ICH M12 guidance recommend examining CES-mediated metabolism for drugs that do not undergo significant metabolism by CYP enzymes. CES primarily hydrolyze esters, amides, thioesters, and carbamates. Ester prodrugs are designed to be hydrolyzed to their pharmacologically active metabolite by CES. In addition, novel non-viral drug delivery modalities such as lipid nanoparticles may take advantage of ester hydrolysis for the release of their payload.

This presentation will provide an overview of the current understanding of the role of CES in drug metabolism, factors affecting the expression and activity of CES, tissue distribution, species differences, and potential DDI.

Key concepts discussed in this webinar will include:

Introduction to carboxylesterases
Cellular location, tissue distribution, and species differences
Drug substrate examples
Novel drug delivery modalities utilizing ester hydrolysis
Factors affecting the expression and activity of carboxylesterases
Potential drug-drug interactions
In vitro assays to evaluate drug victim and perpetrator potential associated with carboxylesterases

About the Presenter

Pallavi Limaye, PhD brings ADME-DDI, toxicology, and liver pathobiology expertise to BioIVT’s consulting team. Pallavi obtained her Ph.D. in toxicology from the University of Louisiana at Monroe and completed postdoctoral research at the University of Pittsburgh and University of Kansas Medical Center.

Dr. Limaye's experience includes serving as a study director for in vitro drug metabolism studies at XenoTech, Senior Scientist at Xenometrics LLC, where I was a study director for regulated nonclinical IND- and NDA-enabling toxicology studies, and Principal Scientist at MRIGlobal where I oversaw nonclinical toxicology and animal health studies, as well as contributed to containment research with select chemical agents.

First name*

Last name*

Company name*

Confirm your email:*

Confirm your country of residence:*

Please check the boxes if you are happy to receive email communications from us in relation to:

Webinars, conferences, presentations and/or events that BioIVT and other group companies are hosting, facilitating and/or sponsoring and that we think you might be interested in;

White papers, editorials and other materials that BioIVT and other group companies produce, author, co-author and/or contribute and to that we think you might be interested in;

Ready-to-ship product updates and availability notices;

BioIVT and other group company products, services, surveys and news that we think you might be interested in;

You can unsubscribe from these communications at any time by emailing privacy@bioivt.com or by following the opt-out links on any communication we send you. We will only process your personal data as set out in our Privacy Policy.

I would like to unsubscribe from all BioIVT email communications.

I have read and understand our Privacy Policy.*

CARBOXYLESTERASES IN DRUG METABOLISM: CHALLENGES AND OPPORTUNITIES

REGISTER TO ACCESS THE RECORDING & SLIDES